Pd41-06 Evaluation of the Tumor Microenvironment of Upper Tract Urothelial Carcinoma Using Multiplex Fluorescence Immunohistochemistry

You have accessJournal of UrologyBladder Cancer: Upper Tract Transitional Cell Carcinoma III (PD41)1 May 2024PD41-06 EVALUATION OF THE TUMOR MICROENVIRONMENT OF UPPER TRACT UROTHELIAL CARCINOMA USING MULTIPLEX FLUORESCENCE IMMUNOHISTOCHEMISTRY Kenta Takahashi, Daiki Ikarashi, Tatsuya Kawamura, Ei Shiomi, Tomohiko Matsuura, Shigekatsu Maekawa, Renpei Kato, Mitsugu Kanehira, Jun Sugimura, Takaya Abe, and Wataru Obara Kenta TakahashiKenta Takahashi , Daiki IkarashiDaiki Ikarashi , Tatsuya KawamuraTatsuya Kawamura , Ei ShiomiEi Shiomi , Tomohiko MatsuuraTomohiko Matsuura , Shigekatsu MaekawaShigekatsu Maekawa , Renpei KatoRenpei Kato , Mitsugu KanehiraMitsugu Kanehira , Jun SugimuraJun Sugimura , Takaya AbeTakaya Abe , and Wataru ObaraWataru Obara View All Author Informationhttps://doi.org/10.1097/01.JU.0001008568.76803.f1.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Bladder cancer was recently classified at the molecular level, including a detailed analysis conducted on oncogene mutations and the tumor microenvironment. However, the association between oncogene mutations and the tumor microenvironment in upper tract urothelial carcinoma is unclear. The aim of this study was to determine the relationship between the tumor microenvironment and the characteristic oncogene mutations in patients with upper tract urothelial carcinoma using multiplex fluorescent immunohistochemistry. METHODS: We evaluated tumor specimens from 17 patients who underwent nephroureterectomy for upper tract urothelial carcinoma and oncogene mutation analysis. The density of each immune cell type, including CD4+ T cells, CD8+ T cells, CD4+Foxp3+ T cells, and CD204+ cells was assessed in the intratumoral and peritumoral areas between fibroblast growth factor receptor (FGFR)3, tumor protein (TP)53, and RAS mutations via multiplex fluorescent immunohistochemistry. RESULTS: The median patient age was 72 (61–82) years, and 12 (70%) patients were men. The primary lesions included renal pelvis cancer in nine patients and ureteral cancer in eight patients. Five patients (16%) received neoadjuvant chemotherapy. Genetic mutation analysis revealed FGFR3, TP53, and RAS mutations in six (35%), four (24%), and one patient (6%), respectively. Seven patients were ≥ pT3 or ypT2, and ten patients were < pT2 or ypT1. Patients with ≥ pT3 or ypT2 tended to have a lower density of immune cells in the intratumoral area compared with the density in other patients. Interestingly, patients with FGFR3 mutations tended to have a lower density of immune cells in the intratumoral areas compared with patients having TP53 or RAS mutations, regardless of pT stage (Figure 1). CONCLUSIONS: Patients with FGFR3 mutations tended to have fewer intratumoral and peritumoral immune cells, suggesting that the therapeutic effect of immune checkpoint inhibitors alone as adjuvant therapy may be limited in these patients. Download PPT Source of Funding: The authors declare no source of funding © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e888 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Kenta Takahashi More articles by this author Daiki Ikarashi More articles by this author Tatsuya Kawamura More articles by this author Ei Shiomi More articles by this author Tomohiko Matsuura More articles by this author Shigekatsu Maekawa More articles by this author Renpei Kato More articles by this author Mitsugu Kanehira More articles by this author Jun Sugimura More articles by this author Takaya Abe More articles by this author Wataru Obara More articles by this author Expand All Advertisement PDF downloadLoading ...